These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 33658587)

  • 1. Cell-free DNA concentration and fragment size as a biomarker for prostate cancer.
    Chen E; Cario CL; Leong L; Lopez K; Márquez CP; Chu C; Li PS; Oropeza E; Tenggara I; Cowan J; Simko JP; Chan JM; Friedlander T; Wyatt AW; Aggarwal R; Paris PL; Carroll PR; Feng F; Witte JS
    Sci Rep; 2021 Mar; 11(1):5040. PubMed ID: 33658587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
    Mehra N; Dolling D; Sumanasuriya S; Christova R; Pope L; Carreira S; Seed G; Yuan W; Goodall J; Hall E; Flohr P; Boysen G; Bianchini D; Sartor O; Eisenberger MA; Fizazi K; Oudard S; Chadjaa M; Macé S; de Bono JS
    Eur Urol; 2018 Sep; 74(3):283-291. PubMed ID: 29500065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing.
    Chen E; Cario CL; Leong L; Lopez K; Márquez CP; Li PS; Oropeza E; Tenggara I; Cowan J; Simko JP; Kageyama R; Wells DK; Chan JM; Friedlander T; Aggarwal R; Paris PL; Feng F; Carroll PR; Witte JS
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the Diagnostic Value of Plasma-Free DNA in Prostate Cancer Screening.
    Seyedolmohadessin SM; Akbari MT; Nourmohammadi Z; Basiri A; Pourmand G
    Iran Biomed J; 2018 Sep; 22(5):331-7. PubMed ID: 29475366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis.
    Ponti G; Maccaferri M; Manfredini M; Micali S; Torricelli F; Milandri R; Del Prete C; Ciarrocchi A; Ruini C; Benassi L; Bettelli S; Kaleci S; Ozben T; Tomasi A
    Clin Chim Acta; 2019 Oct; 497():76-80. PubMed ID: 31301282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA.
    Abramovic I; Pezelj I; Dumbovic L; Skara Abramovic L; Vodopic T; Bulimbasic S; Stimac G; Bulic-Jakus F; Kulis T; Katusic Bojanac A; Tomas D; Ulamec M; Sincic N
    Prostate; 2024 Sep; 84(12):1128-1137. PubMed ID: 38824441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer.
    Kubota Y; Hatakeyama S; Yoneyama T; Yoneyama MS; Hamano I; Konishi S; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Ohyama C
    World J Urol; 2021 Sep; 39(9):3265-3271. PubMed ID: 33675416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer.
    Schütz E; Akbari MR; Beck J; Urnovitz H; Zhang WW; Bornemann-Kolatzki K; Mitchell WM; Nam RK; Narod SA
    Clin Chem; 2015 Jan; 61(1):239-48. PubMed ID: 25348670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
    Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ
    Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
    Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating mRNA signature as a marker for high-risk prostate cancer.
    Souza MF; Kuasne H; Barros-Filho MC; Cilião HL; Marchi FA; Fuganti PE; Rogatto SR; Cólus IMS
    Carcinogenesis; 2020 Apr; 41(2):139-145. PubMed ID: 31305891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate-specific antigen.
    Feng J; Gang F; Li X; Jin T; Houbao H; Yu C; Guorong L
    Int Urol Nephrol; 2013 Aug; 45(4):1023-8. PubMed ID: 23779229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
    Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
    Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform.
    Lin E; Hahn AW; Nussenzveig RH; Wesolowski S; Sayegh N; Maughan BL; McFarland T; Rathi N; Sirohi D; Sonpavde G; Swami U; Kohli M; Rich T; Sartor O; Yandell M; Agarwal N
    Oncologist; 2021 Sep; 26(9):751-760. PubMed ID: 34157173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
    Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
    Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer.
    Du M; Tian Y; Tan W; Wang L; Wang L; Kilari D; Huang CC; Wang L; Kohli M
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):705-713. PubMed ID: 32203070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.
    Hagiwara K; Tobisawa Y; Kaya T; Kaneko T; Hatakeyama S; Mori K; Hashimoto Y; Koie T; Suda Y; Ohyama C; Yoneyama T
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134773
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer.
    Watahiki A; Macfarlane RJ; Gleave ME; Crea F; Wang Y; Helgason CD; Chi KN
    Int J Mol Sci; 2013 Apr; 14(4):7757-70. PubMed ID: 23574937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
    Fettke H; Kwan EM; Docanto MM; Bukczynska P; Ng N; Graham LK; Mahon K; Hauser C; Tan W; Wang XH; Zhao Z; Zheng T; Zhou K; Du P; Yu J; Huang Y; Jia S; Kohli M; Horvath LG; Azad AA
    Eur Urol; 2020 Aug; 78(2):173-180. PubMed ID: 32487321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.